Kostas Biliouris
Stock Analyst at Oppenheimer
(1.06)
# 3,876
Out of 4,630 analysts
432
Total ratings
40%
Success rate
-0.6%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kostas Biliouris
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRPT Sarepta Therapeutics | Maintained: Buy | $37 → $35 | $16.78 | +108.58% | 38 | Aug 6, 2026 | |
| OVID Ovid Therapeutics | Rated: Buy | $9 | $2.63 | +242.21% | 1 | Aug 3, 2026 | |
| ALNY Alnylam Pharmaceuticals | Maintained: Buy | $500 → $350 | $219.20 | +59.67% | 41 | Jul 31, 2026 | |
| PRME Prime Medicine | Reiterated: Buy | $11 | $3.08 | +257.14% | 19 | Jul 24, 2026 | |
| NRIX Nurix Therapeutics | Maintained: Buy | $28 | $25.53 | +9.67% | 2 | Jul 10, 2026 | |
| PRQR ProQR Therapeutics | Maintained: Buy | $9 | $1.88 | +380.00% | 3 | Jul 6, 2026 | |
| IRD Opus Genetics | Reiterated: Buy | $10 | $3.66 | +173.22% | 2 | Jun 17, 2026 | |
| LEGN Legend Biotech | Maintained: Buy | $75 | $20.75 | +261.45% | 59 | Jun 15, 2026 | |
| DSGN Design Therapeutics | Reiterated: Buy | $21 | $13.99 | +50.11% | 4 | Jun 15, 2026 | |
| DTIL Precision BioSciences | Initiated Coverage: Buy | $20 | $7.49 | +167.02% | 21 | Jun 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $23 | $6.87 | +234.79% | 4 | Jun 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $50 | $14.08 | +255.11% | 3 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $55.82 | $13.73 | +306.54% | 2 | Apr 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $15 | $2.85 | +426.32% | 3 | Mar 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $22 | $13.25 | +66.04% | 18 | Mar 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $63.81 | - | 31 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $56.56 | - | 27 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $3.61 | - | 5 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $11.94 | - | 25 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $84.48 | - | 12 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $27.48 | - | 23 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.7095 | - | 4 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $26.25 | - | 5 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $11.95 | - | 14 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $10.75 | - | 30 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.23 | - | 9 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $75 | $53.52 | +40.13% | 20 | Sep 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $5.36 | n/a | 6 | Jan 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $77 | $293.15 | n/a | 1 | Jun 16, 2022 |
Sarepta Therapeutics
Aug 6, 2026
Maintained: Buy
Price Target: $37 → $35
Current: $16.78
Upside: +108.58%
Ovid Therapeutics
Aug 3, 2026
Rated: Buy
Price Target: $9
Current: $2.63
Upside: +242.21%
Alnylam Pharmaceuticals
Jul 31, 2026
Maintained: Buy
Price Target: $500 → $350
Current: $219.20
Upside: +59.67%
Prime Medicine
Jul 24, 2026
Reiterated: Buy
Price Target: $11
Current: $3.08
Upside: +257.14%
Nurix Therapeutics
Jul 10, 2026
Maintained: Buy
Price Target: $28
Current: $25.53
Upside: +9.67%
ProQR Therapeutics
Jul 6, 2026
Maintained: Buy
Price Target: $9
Current: $1.88
Upside: +380.00%
Opus Genetics
Jun 17, 2026
Reiterated: Buy
Price Target: $10
Current: $3.66
Upside: +173.22%
Legend Biotech
Jun 15, 2026
Maintained: Buy
Price Target: $75
Current: $20.75
Upside: +261.45%
Design Therapeutics
Jun 15, 2026
Reiterated: Buy
Price Target: $21
Current: $13.99
Upside: +50.11%
Precision BioSciences
Jun 9, 2026
Initiated Coverage: Buy
Price Target: $20
Current: $7.49
Upside: +167.02%
Jun 3, 2026
Reiterated: Buy
Price Target: $23
Current: $6.87
Upside: +234.79%
May 15, 2026
Reiterated: Buy
Price Target: $50
Current: $14.08
Upside: +255.11%
Apr 20, 2026
Reiterated: Buy
Price Target: $55.82
Current: $13.73
Upside: +306.54%
Mar 31, 2026
Reiterated: Buy
Price Target: $15
Current: $2.85
Upside: +426.32%
Mar 13, 2026
Reiterated: Buy
Price Target: $22
Current: $13.25
Upside: +66.04%
Sep 25, 2025
Rated: Hold
Price Target: n/a
Current: $63.81
Upside: -
Sep 25, 2025
Rated: Hold
Price Target: n/a
Current: $56.56
Upside: -
Sep 25, 2025
Rated: Hold
Price Target: n/a
Current: $3.61
Upside: -
Sep 25, 2025
Rated: Hold
Price Target: n/a
Current: $11.94
Upside: -
Sep 25, 2025
Rated: Hold
Price Target: n/a
Current: $84.48
Upside: -
Sep 25, 2025
Rated: Hold
Price Target: n/a
Current: $27.48
Upside: -
Sep 25, 2025
Rated: Hold
Price Target: n/a
Current: $0.7095
Upside: -
Sep 25, 2025
Rated: Hold
Price Target: n/a
Current: $26.25
Upside: -
Sep 25, 2025
Rated: Hold
Price Target: n/a
Current: $11.95
Upside: -
Sep 25, 2025
Rated: Hold
Price Target: n/a
Current: $10.75
Upside: -
Sep 25, 2025
Rated: Hold
Price Target: n/a
Current: $1.23
Upside: -
Sep 23, 2025
Reiterated: Buy
Price Target: $75
Current: $53.52
Upside: +40.13%
Jan 29, 2024
Rated: Hold
Price Target: n/a
Current: $5.36
Upside: n/a
Jun 16, 2022
Initiated Coverage: Buy
Price Target: $77
Current: $293.15
Upside: n/a